LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

Show other versions (1)

Background: Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients. Material and methods: From January 2001 to September 2006 we treated with imatini...

Full description

Bibliographic Details
Published in:	Mediterranean Journal of Hematology and Infectious Diseases
Main Authors:	Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena
Format:	Article
Language:	English
Published:	PAGEPress Publications 2011-05-01
Subjects:	chronic myeloid leukemia, imatinib, infections, bacterial, herpes Zoster
Online Access:	http://www.mjhid.org/index.php/mjhid/article/view/303

Similar Items

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
by: Michelina Santopietro, et al.
Published: (2011-01-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01)

Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
by: Bassam Francis Matti, et al.
Published: (2013-12-01)

Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
by: D C Doval, et al.
Published: (2013-01-01)

Generic Imatinib Mesylate as first-line treatment of chronic myeloid leukemia.
by: Brahim Benzineb, et al.
Published: (2023-04-01)

Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia
by: Arthur Gomes Oliveira Braga, et al.
Published: (2024-07-01)

Second-Line Therapy Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia Resistant to Imatinib
by: Chici Pratiwi, et al.
Published: (2022-12-01)

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data
by: Michiels S, et al.
Published: (2024-09-01)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
by: Olga Meltem Akay, et al.
Published: (2016-05-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01)

Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells
by: Sylwester Głowacki, et al.
Published: (2021-04-01)

Frequency of Hematological Response in Patients with Chronic Myeloid Leukemia (Chronic Phase) with Imatinib After Three Months Presenting to CMH Rawalpindi
by: Anil Babar, et al.
Published: (2024-04-01)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
by: Katerina Arvaniti, et al.
Published: (2014-07-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
by: Fang Cheng, et al.
Published: (2023-05-01)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
by: Kamran Moshfeghi, et al.
Published: (2013-01-01)

Reacciones adversas del imatinib como droga de segunda línea en pacientes con leucemia mieloide crónica Adverse reactions to imatinib as second-line drug in patients with chronic myeloid leukemia
by: Onel M. Ávila Cabrera, et al.
Published: (2010-12-01)

Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients
by: Ali M. Jawad, et al.
Published: (2008-10-01)

Nilotinib therapy after resistance to imatinib
by: Raffaele Porrini, et al.
Published: (2015-10-01)

Profile of pediatric chronic myeloid leukemia in the era of imatinib: A study from South India
by: Catherene Bernard, et al.
Published: (2019-01-01)

Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
by: Mozafar Aznab, et al.
Published: (2021-01-01)

Genomic analysis identifies an incipient signature to forecast imatinib resistance before start of treatment in patients with chronic myeloid leukemia
by: Rahul Mojidra, et al.
Published: (2025-01-01)

Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience
by: Wael Abdelgawad Edesa, et al.
Published: (2015-06-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
by: Abolghasem Allahyari, et al.
Published: (2016-03-01)

Nilotinib therapy after resistance and intolerance to imatinib in CML patient with trisomy of the chromosome 8
by: Antonella Russo Rossi
Published: (2015-10-01)

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate
by: Senthil Rajappa, et al.
Published: (2013-01-01)

Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag
by: Francesco Autore, et al.
Published: (2021-12-01)

Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines
by: Raquel Alves, et al.
Published: (2023-01-01)

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
by: Petra Belohlavkova, et al.
Published: (2018-02-01)

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
by: G Rogers, et al.
Published: (2012-04-01)

Pharmaceutical inhibition of BCL6 ameliorates resistance to imatinib in chronic myeloid leukemia
by: Yingying Xiao, et al.
Published: (2024-08-01)

Imatinib Use in Pregnancy
by: Michael J Webb, et al.
Published: (2012-12-01)

Cytogenetic Response Assessment to Imatinib Mesylate Therapy for Chronic Myeloid Leukemia in Iraqi Patients
by: Azhar M Haleem
Published: (2020-06-01)

Cytogenetic Response Assessment to Imatinib Mesylate Therapy for Chronic Myeloid Leukemia in Iraqi Patients
by: Azhar M Haleem
Published: (2020-06-01)